Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03473756
Title Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma (FORT-2)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Bayer
Indications

urethra transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

Therapies

Atezolizumab

Atezolizumab + Rogaratinib

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST